German Breast Group - Clinical Reasearch under better Conditions

"Healing through innovation, competence and partnership" has been the vision of the GBG Research Institute since its foundation in April 2003.

These cornerstones of our work allow us professional handling of clinical trials with the highest quality standards, maximum scientific independence and professional neutrality.

Clinical trials exploring new methods of treatment nowadays represent a central element of medical research. In order to achieve a balanced level of knowledge, we consider it to be indispensable that clinical trials are conducted not only by manufacturers of pharmaceutics and medicinal products, but also by academic groups.

Significant to the success of our clinical trials is our collaboration and partnership with investigators and trial staff and their trial participants, as well as the manufacturers of pharmaceutics. We have at our disposal a network of approximately 500 study sites and 1000 clinical investigators. Furthermore, we cooperate with a multitude of both national and international study groups as well as most of the pharmaceutical companies which develop drugs for the treatment of breast cancer.

 

GBG Trials from San Antonio 2014

M. Untch presenting at SABCS 2014

This year GBG could again present its trials successfully at the San Antonio Breast Cancer Symposium.
We are proud to present the presentaions here.

GBG32 ICE -  Efficacy
Gunter von Minckwitz: The phase III ICE study: Adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer

GBG69 GeparSepto - Final Analysis
Michael Untch: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto)

EDUCATIONAL SESSION: HER2 Positive Breast Cancer: Insights from the Lab and Clinic
Sibylle Loibl: Neoadjuvant therapy in HER2 positive breast cancer, latest developments and biomarkers and how it serves as a discovery platform

Poster Presentations

Sibylle Loibl: Predicting residual risk of recurrence after neoadjuvant chemotherapy- a retrospective analysis of EndoPredict® in the GeparTrio trial

Bernd Gerber: Neoadjuvant chemotherapy with or without bevacizumab or everolimus: Survival analysis of The HER2-negative cohort of the GEPARQUINTO study (GBG 44)

Sibylle Loibl: PD5-7 PTEN and PIK3CA but not p4EBP1 are associated with low rates of pathological complete response (pCR) to trastuzumab based chemotherapy in primary HER2-overexpressing breast cancer

   

GAIN-2 - The trial for high-risk breast cancer

The  typical GAIN-2-patient:

  • HER2-positive or triple-negative tumor irrespective of nodal status or
  • Luminal B-tumor (ER and/or PgR-positive, HER2-negative, Ki-67 > 20%) with positive lymph nodes or
  • at least 4 affected lymph nodes.

Trial design:

More about this trial is found here.

   

GBG Jahrestreffen 2015

Das nächste GBG-Jahrestreffen wird am 26. und 27. Februar 2015 in Frankfurt stattfinden.
Updates zu den Studien:
Aktueller Stand laufender Studien, Vorstellung neuer Studienkonzepte, Präsentation jüngster Ergebnisse
Das vorläufige Programm des GBG Jahrestreffens 2015 finden Sie hier.

Save the Date-Flyer

Key Note Speaker: Charles M. Perou, PhD (USA) & Univ. Professor Dr. Dr.h.c. Christoph Zielinski (Österreich)

Workshops: Nebenwirkungs-Management, Gesundheitsökonomische Datenerhebung im Rahmen klinischer Studien, TraFo und Zentralpathologie und weitere.

Read more: GBG Jahrestreffen 2015

   

more news

more News...